Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | TP53 |
| Variant | negative |
| Impact List | unknown |
| Protein Effect | loss of function |
| Gene Variant Descriptions | TP53 negative indicates a lack of the TP53 gene, mRNA, and/or protein. |
| Associated Drug Resistance | |
| Category Variants Paths |
TP53 mutant TP53 inact mut TP53 negative |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04592237 | Phase II | Niraparib Cabazitaxel + Carboplatin + Cetrelimab Cetrelimab + Niraparib | Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer | Active, not recruiting | USA | 0 |
| NCT03560882 | Phase I | Atorvastatin | A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies | Active, not recruiting | USA | 0 |